Loading stock data…
$3.60+0.03 (+0.70%)
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Taysha Gene Therapies, Inc. in the Healthcare sector is trading at $3.60 with a market capitalization of $1.6B. Wall Street consensus targets $13.00 (13 analysts), implying a +260.6% move over the next 12 months. The stock is currently near its 52-week low of $3.46, remaining 33.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $5.49M | $0↓ | $1.99M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$50.78M↓ | -$43.49M↓ | -$28.30M↑ | -$34.02M↓ | -$26.75M |
| Net Income | -$46.64M↓ | -$42.41M↓ | -$27.85M↑ | -$32.73M↓ | -$26.88M |
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company prima...